Differential expression analysis from the cross-platform normalized data showed that there were significant differences in CaMK2A expression in the HP, EC and TC between the AD patients and the control subjects (|log FC| > 0.1, P < 0.05); however, only the differences in the HP and TC remained following the multiple comparisons correction (FDR-corrected P = 0.034, P = 0.017, respectively). This evidence concerns the gene CAMK2A and Alzheimer disease.